Sotera Health Signals Steady Growth In Earnings Call

Sotera Health Company ((SHC)) has held its Q1 earnings call. Read on for the main highlights of the call.

Sotera Health set a confident tone in its latest earnings call, highlighting double‑digit revenue growth, expanding margins, and stronger earnings even as management acknowledged select pockets of pressure. Management emphasized improved legal positioning, solid liquidity, and a reaffirmed outlook, arguing that operational execution is outpacing identifiable risks in testing, FX, and regulatory areas.

Consolidated Revenue Growth

Sotera Health reported Q1 2026 revenue of $280 million, up 10% year over year, or 6.5% on a constant currency basis, underscoring broad-based demand across its portfolio. Management noted that foreign exchange provided a tailwind, but stressed that underlying volume and pricing trends were the primary drivers of the top-line advance.

Adjusted EBITDA and Margin Expansion

Adjusted EBITDA increased 10.5% to $135 million, translating to 6.9% growth on a constant currency basis and more than 20 basis points of margin expansion. The company framed this as evidence of operating discipline, as revenue gains flowed through to profits despite inflation, regulatory investments, and selective volume pressure in parts of the business.

Strong Adjusted EPS Improvement

Adjusted EPS climbed to $0.18 in Q1 2026, an improvement of about 29% versus the prior-year quarter, reflecting better operating performance and lower interest costs. Management positioned this EPS growth as a sign that the balance sheet and income statement are both trending in the right direction despite elevated capex and legal cash outflows.

Nordion Outperformance and Margin Surge

Nordion stood out with revenue jumping 29% to $42 million, or 25.8% on a constant currency basis, driven mainly by a 23.7% volume and mix lift, plus FX and pricing benefits. Segment income rose roughly 36% and margins expanded more than 290 basis points to 56.4%, though management cautioned that harvest timing and FX made Q1 unusually strong.

Sterigenics Revenue and Pricing Strength

Sterigenics delivered revenue of $186 million, up 9.7% reported and 6.1% in constant currency, supported by 4.5% pricing, 3.6% FX tailwinds, and modest 1.6% volume and mix growth. Segment income increased 9.6% to $96 million, highlighting the pricing power and resilience of the sterilization business even amid maintenance downtime and weather-related disruptions.

Legal Win on Bellwether Cases

Investors’ legal overhang eased as a Georgia State Court dismissed the remaining five Phase 1 bellwether cases on March 30, 2026, bringing total dismissals to eight. Management characterized the decisions as a meaningful rejection of plaintiffs’ general causation theories, while acknowledging that appeals remain possible and legal risk has not disappeared entirely.

Stronger Capital and Liquidity Position

The company ended the quarter with more than $900 million of available liquidity and reported net leverage of 3.2x, edging closer to its 2.0x–3.0x target range. Operating cash flow of $29 million included a $34 million legal settlement payment, which weighed on near-term free cash flow but underscored the balance sheet’s capacity to absorb legal costs.

Board and Leadership Enhancements

Governance moved into focus as Sotera added experienced directors Rich Kyle and Ken Krausz to its board and announced a leadership transition at the top. Chairman and CEO Michael Petras will shift to the role of Executive Chair, with Alton Shader taking over as CEO in May 2026, a move framed as an orderly succession to support the next phase of growth.

Nelson Labs Revenue and Margin Pressure

Nelson Labs was the main soft spot, with revenue slipping 0.7% to $52 million, or 3.8% lower on a constant currency basis, reflecting weaker volume and mix. Segment income fell 11.5% to $15 million and margins retreated to 28%, as the business continues to work through prior headwinds while management targets a gradual recovery over the year.

Timing, FX, and Harvest Dependencies

Management highlighted that Nordion’s outsized performance benefited from favorable Cobalt‑60 harvest schedules and FX tailwinds, which may not repeat in later quarters. The full-year outlook includes an estimated 100 basis point foreign exchange benefit, largely in the first half, underlining some reliance on macro factors and timing for reported growth.

Sterigenics Weather and Downtime Variability

Within Sterigenics, U.S. volumes faced a 1.7% headwind from localized weather, while ethylene oxide maintenance and downtime weighed on first-half throughput. The company expects those maintenance-related constraints to turn into a second-half tailwind, signaling that quarterly variability in volumes may mask a steadier underlying demand picture.

Operating Cash Flow and Legal Outflows

Operating cash flow reached $29 million in the quarter but was depressed by a $34 million legal settlement payment, muting reported free cash generation. Management emphasized that adjusted free cash flow remains positive and should accelerate later in the year as settlement payments ease and earnings growth and margin gains translate more fully into cash.

Elevated Capital Expenditures

Capital expenditures totaled $46 million in Q1, with full-year guidance of $175 million to $225 million targeting Sterigenics capacity expansions, EO upgrades, and Cobalt‑60 projects. While this capex represents a meaningful near-term use of cash, the company argues it is necessary to support long-term growth, regulatory compliance, and enhanced service capabilities.

Net Leverage Above Long-Term Target

Net leverage at 3.2x remains slightly above Sotera’s long-term target range of 2.0x–3.0x, highlighting that deleveraging is still a work in progress. Management expects leverage to improve through 2026 as earnings grow and capex normalizes, but investors will watch closely to ensure balance-sheet discipline keeps pace with the investment cycle.

Regulatory Uncertainty Around Ethylene Oxide

Proposed changes to ethylene oxide emissions rules are creating industry-wide regulatory uncertainty, even as the administration considers scaling back or modifying prior proposals. Sotera noted it has already invested around $200 million historically to meet existing rules and is moving ahead with those standards, while acknowledging that final regulatory outcomes could influence customer behavior and competitive dynamics.

Forward-Looking Guidance and Outlook

Management reaffirmed 2026 guidance for revenue of $1.233 billion to $1.251 billion, implying 5.0%–6.5% constant-currency growth and about a 100 basis point FX tailwind, mainly in the first half. Adjusted EBITDA is projected at $632 million to $641 million and adjusted EPS at $0.93 to $1.01, with plans for capex of $175 million to $225 million, interest expense of $135 million to $145 million, and continued leverage improvement without relying on M&A.

Sotera Health’s earnings call painted a picture of a company executing well on growth and margin expansion while working through targeted challenges in testing and regulatory investments. For investors, the reaffirmed guidance, legal wins, and robust liquidity suggest a constructive risk-reward profile, provided management can deliver on Nelson Labs’ recovery and navigate evolving EO regulations.